Enlightening patients about the ocular impact of not adhering to glaucoma medication regimens can be eye-opening for both the patients and physicians.
A recent study found that the overall topical glaucoma medication adherence rate for inpatients with a diagnosis of glaucoma was 75.3%. This rate increased to 85.1% among inpatients after providers were educated about the importance of continuous glaucoma treatment, according to Danny Mammo, MD, a senior resident at the Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis.
From the ophthalmologist’s perspective, strict adherence to glaucoma medication cannot be overemphasized. However, from the perspective of other medical specialists, the reasons for strict adherence are not always readily apparent given the nature of the disease. Sometimes, information about a prescribed glaucoma medication may not be available upon patient admission.
“Appropriate medication compliance has significant implications for ocular health,” Dr. Mammo said. He pointed out that by 2050, approximately 7.32 million people in the United States will have primary open-angle glaucoma. Most previous research in anti-glaucoma medication regimen adherence has focused almost solely on outpatient adherence to these regimens.
One study that addressed inpatient adherence took a look at hospitalizations from 2006 to 2009 (J Glaucoma 2011;20:573-6) and reported an adherence rate to topical anti-glaucoma medications of 51.6%. Since that time, when less than 10% of hospital used electronic medical records, many more hospitals (83.8%) have adopted electronic medical records-keeping. In light of this, Dr. Mammo and colleagues conducted a study in which they assessed adherence to topical anti-glaucoma medication regimens in an inpatient setting before and after an educational intervention of relevant health care providers took place.
Danny Mammo, MD
E: [email protected]
This article is based on Dr. Mammo’s presentation at the American Academy of Ophthalmology 2019 annual meeting. Dr. Mammo has no financial interest in any aspect of this report.